{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:08:28Z","timestamp":1758636508178},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Tumor lysis syndrome is an oncologic emergency that involves multiple metabolic abnormalities and clinical symptoms such as acute renal failure, cardiac arrhythmias, seizures, and multiorgan failure, and may be fatal if not promptly recognized. Tumor lysis syndrome occurs most often in patients with hematologic malignancies, and relatively few cases have been described in patients with sarcoma.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 64-year-old male of Asian heritage presented to his primary care physician with a right lower-extremity mass and was ultimately diagnosed with widely metastatic osteosarcoma. He was treated with one cycle of cisplatin and doxorubicin that was complicated by hypervolemia and hypoxic respiratory failure. Given concerns for volume overload, therapy was changed to single-agent, dose-reduced ifosfamide. After receiving one dose of ifosfamide 1\u00a0g\/m<jats:sup>2<\/jats:sup> (1.8\u00a0g total) intravenously over 1\u00a0hour, the patient developed renal failure, hyperuricemia, hyperkalemia, hyperphosphatemia, and lactic acidosis. The patient ultimately died from severe electrolyte abnormalities associated with tumor lysis syndrome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This is the first instance of tumor lysis syndrome described in a patient with osteosarcoma undergoing ifosfamide monotherapy. Clinicians must be vigilant in identifying tumor lysis syndrome regardless of the malignancy type or chemotherapy regimen in order to prevent potentially fatal complications.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-022-03469-6","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T23:05:52Z","timestamp":1656371152000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Tumor lysis syndrome following ifosfamide monotherapy in metastatic osteosarcoma: a case report and review of the literature"],"prefix":"10.1186","volume":"16","author":[{"given":"Steven N.","family":"Luminais","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darwin","family":"Roman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander B.","family":"Christ","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James S.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,28]]},"reference":[{"key":"3469_CR1","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1200\/JCO.2002.20.3.776","volume":"20","author":"SS Bielack","year":"2002","unstructured":"Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et\u00a0al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776\u201390.","journal-title":"J Clin Oncol"},{"key":"3469_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1752-1947-4-70","volume":"4","author":"C Papandreou","year":"2010","unstructured":"Papandreou C, Skopelitou A, Kappes G, et\u00a0al. Primary osteosarcoma of the urinary bladder treated with external radiotherapy in a patient with a history of transitional cell carcinoma: a case report. J Med Case Rep. 2010;4:70.","journal-title":"J Med Case Rep"},{"key":"3469_CR3","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1002\/cncr.24121","volume":"115","author":"L Mirabello","year":"2009","unstructured":"Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115:1531\u201343.","journal-title":"Cancer"},{"key":"3469_CR4","first-page":"59","volume":"40","author":"LM Duong","year":"2013","unstructured":"Duong LM, Richardson LC. Descriptive epidemiology of malignant primary osteosarcoma using population-based registries, United States, 1999\u20132008. J Registry Manag. 2013;40:59\u201364.","journal-title":"J Registry Manag"},{"key":"3469_CR5","first-page":"92","volume":"9","author":"A Franchi","year":"2012","unstructured":"Franchi A. Epidemiology and classification of bone tumors. Clin Cases Miner Bone Metab. 2012;9:92\u20135.","journal-title":"Clin Cases Miner Bone Metab"},{"key":"3469_CR6","unstructured":"Key Statistics About Bone Cancer. American Cancer Society. 2020. https:\/\/www.cancer.org\/cancer\/bone-cancer\/about\/key-statistics.html."},{"key":"3469_CR7","doi-asserted-by":"publisher","first-page":"4522","DOI":"10.1002\/cncr.26037","volume":"117","author":"IF Ciernik","year":"2011","unstructured":"Ciernik IF, Niemierko A, Harmon DC, Kobayashi W, Chen Y-L, Yock TI, et\u00a0al. Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma. Cancer. 2011;117:4522\u201330.","journal-title":"Cancer"},{"key":"3469_CR8","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1200\/JCO.1992.10.10.1579","volume":"10","author":"VH Bramwell","year":"1992","unstructured":"Bramwell VH, Burgers M, Sneath R, Souhami R, van Oosterom AT, Vo\u00fbte PA, et\u00a0al. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol. 1992;10:1579\u201391.","journal-title":"J Clin Oncol"},{"key":"3469_CR9","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/jnci\/djk015","volume":"99","author":"IJ Lewis","year":"2007","unstructured":"Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PCW, et\u00a0al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 2007;99:112\u201328.","journal-title":"J Natl Cancer Inst"},{"key":"3469_CR10","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/S0140-6736(97)02307-6","volume":"350","author":"RL Souhami","year":"1997","unstructured":"Souhami RL, Craft AW, Van der Eijken JW, Nooij M, Spooner D, Bramwell VH, et\u00a0al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet. 1997;350:911\u20137.","journal-title":"Lancet"},{"key":"3469_CR11","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1200\/JCO.2000.18.24.4016","volume":"18","author":"G Bacci","year":"2000","unstructured":"Bacci G, Ferrari S, Bertoni F, Ruggieri P, Picci P, Longhi A, et\u00a0al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli\/osteosarcoma-2 protocol: an updated report. J Clin Oncol. 2000;18:4016\u201327.","journal-title":"J Clin Oncol"},{"key":"3469_CR12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1200\/JCO.1988.6.2.329","volume":"6","author":"K Winkler","year":"1988","unstructured":"Winkler K, Beron G, Delling G, Heise U, Kabisch H, Purf\u00fcrst C, et\u00a0al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol. 1988;6:329\u201337.","journal-title":"J Clin Oncol"},{"key":"3469_CR13","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/S1470-2045(16)30214-5","volume":"17","author":"NM Marina","year":"2016","unstructured":"Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, et\u00a0al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016;17:1396\u2013408.","journal-title":"Lancet Oncol"},{"key":"3469_CR14","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1093\/annonc\/mdg286","volume":"14","author":"G Bacci","year":"2003","unstructured":"Bacci G, Briccoli A, Rocca M, Ferrari S, Donati D, Longhi A, et\u00a0al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol. 2003;14:1126\u201334.","journal-title":"Ann Oncol"},{"key":"3469_CR15","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1200\/JCO.1987.5.8.1191","volume":"5","author":"JS Miser","year":"1987","unstructured":"Miser JS, Kinsella TJ, Triche TJ, Tsokos M, Jarosinski P, Forquer R, et\u00a0al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol. 1987;5:1191\u20138.","journal-title":"J Clin Oncol"},{"key":"3469_CR16","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1200\/JCO.2002.20.2.426","volume":"20","author":"AM Goorin","year":"2002","unstructured":"Goorin AM, Harris MB, Bernstein M, Ferguson W, Devidas M, Siegal GP, et\u00a0al. Phase II\/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol. 2002;20:426\u201333.","journal-title":"J Clin Oncol"},{"key":"3469_CR17","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1200\/JCO.18.02374","volume":"37","author":"LE Davis","year":"2019","unstructured":"Davis LE, Bolejack V, Ryan CW, Ganjoo KN, Loggers ET, Chawla S, et\u00a0al. Randomized double-blind phase II study of regorafenib in patients with metastatic osteosarcoma. J Clin Oncol. 2019;37:1424\u201331.","journal-title":"J Clin Oncol"},{"key":"3469_CR18","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1093\/annonc\/mdr151","volume":"23","author":"G Grignani","year":"2012","unstructured":"Grignani G, Palmerini E, Dileo P, Asaftei SD, D\u2019Ambrosio L, Pignochino Y, et\u00a0al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol. 2012;23:508\u201316.","journal-title":"Ann Oncol"},{"key":"3469_CR19","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/S1470-2045(14)71136-2","volume":"16","author":"G Grignani","year":"2015","unstructured":"Grignani G, Palmerini E, Ferraresi V, D\u2019Ambrosio L, Bertulli R, Asaftei SD, et\u00a0al. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncol. 2015;16:98\u2013107.","journal-title":"Lancet Oncol"},{"key":"3469_CR20","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1056\/NEJMra0904569","volume":"364","author":"SC Howard","year":"2011","unstructured":"Howard SC, Jones DP, Pui C-H. The tumor lysis syndrome. N Engl J Med. 2011;364:1844\u201354.","journal-title":"N Engl J Med"},{"key":"3469_CR21","volume-title":"Tumor Lysis Syndrome","author":"A Adeyinka","year":"2020","unstructured":"Adeyinka A, Bashir K. Tumor Lysis Syndrome. StatPearls. Treasure Island: StatPearls Publishing; 2020."},{"key":"3469_CR22","unstructured":"Amaka Edeani AS. Chapter 4: Tumor lysis syndrome. Online Curricula: Onco-Nephrology. American Society of Nephrology; 2016."},{"key":"3469_CR23","first-page":"1","volume":"2","author":"K-Q Qian","year":"2009","unstructured":"Qian K-Q, Ye H, Xiao Y-W, Bao Y-Y, Qi C-J. Tumor lysis syndrome associated with chemotherapy in primary retroperitoneal soft tissue sarcoma by ex vivo ATP-based tumor chemo-sensitivity assay (ATP-TCA). Int J Gen Med. 2009;2:1\u20134.","journal-title":"Int J Gen Med."},{"key":"3469_CR24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/ajh.2830440109","volume":"44","author":"JE Gold","year":"1993","unstructured":"Gold JE, Malamud SC, LaRosa F, Osband ME. Adoptive chemoimmunotherapy using ex vivo activated memory T-cells and cyclophosphamide: tumor lysis syndrome of a metastatic soft tissue sarcoma. Am J Hematol. 1993;44:42\u20137.","journal-title":"Am J Hematol"},{"key":"3469_CR25","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3109\/08880019309016549","volume":"10","author":"J Khan","year":"1993","unstructured":"Khan J, Broadbent VA. Tumor lysis syndrome complicating treatment of widespread metastatic abdominal rhabdomyosarcoma. Pediatr Hematol Oncol. 1993;10:151\u20135.","journal-title":"Pediatr Hematol Oncol"},{"key":"3469_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.gore.2019.02.006","volume":"28","author":"Z Ahmed","year":"2019","unstructured":"Ahmed Z, Barefah A, Wasi P, Jones G, Ramsay J. Tumour lysis syndrome in a patient with undifferentiated endometrial stromal sarcoma. Gynecol Oncol Rep. 2019;28:41\u20133.","journal-title":"Gynecol Oncol Rep."},{"key":"3469_CR27","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/j.1447-0756.2010.01454.x","volume":"37","author":"Y Hiraizumi","year":"2011","unstructured":"Hiraizumi Y, Kamoi S, Inde Y, Kurose K, Ohaki Y, Takeshita T. A case of tumor lysis syndrome following chemotherapy for a uterine epithelioid leiomyosarcoma with focal rhabdomyosarcomatous differentiation. J Obstet Gynaecol Res. 2011;37:947\u201352.","journal-title":"J Obstet Gynaecol Res."},{"key":"3469_CR28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13256-017-1241-3","volume":"11","author":"VE Catania","year":"2017","unstructured":"Catania VE, Vecchio M, Malaguarnera M, Madeddu R, Malaguarnera G, Latteri S. Tumor lysis syndrome in an extraskeletal osteosarcoma: a case report and review of the literature. J Med Case Rep. 2017;11:79.","journal-title":"J Med Case Rep"},{"key":"3469_CR29","volume":"12","author":"D Findakly","year":"2020","unstructured":"Findakly D, Luther RD 3rd, Wang J. Tumor lysis syndrome in solid tumors: a comprehensive literature review, new insights, and novel strategies to improve outcomes. Cureus. 2020;12: e8355.","journal-title":"Cureus."},{"key":"3469_CR30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1053\/j.ackd.2013.07.001","volume":"21","author":"FP Wilson","year":"2014","unstructured":"Wilson FP, Berns JS. Tumor lysis syndrome: new challenges and recent advances. Adv Chronic Kidney Dis. 2014;21:18\u201326.","journal-title":"Adv Chronic Kidney Dis"},{"key":"3469_CR31","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1182\/blood.V120.21.238.238","volume":"120","author":"MS Cairo","year":"2012","unstructured":"Cairo MS, Thompson S, Stern L, Sherman S. Incidence of treatment-related, laboratory and clinical tumor lysis syndrome. Blood. 2012;120:238\u2013238.","journal-title":"Blood"},{"key":"3469_CR32","doi-asserted-by":"crossref","unstructured":"Shafie M, Teymouri A, Parsa S, Sadeghian A, Jalalabadi NZ. Spontaneous tumor lysis syndrome in adrenal adenocarcinoma: a case report and review of the\u00a0literature.\u00a0J Med Case Rep. 2022;16.","DOI":"10.1186\/s13256-022-03263-4"},{"key":"3469_CR33","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/0002-9343(93)90174-N","volume":"94","author":"KR Hande","year":"1993","unstructured":"Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin\u2019s lymphoma. Am J Med. 1993;94:133\u20139.","journal-title":"Am J Med"},{"key":"3469_CR34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3324\/haematol.11575","volume":"93","author":"P Montesinos","year":"2008","unstructured":"Montesinos P, Lorenzo I, Mart\u00edn G, Sanz J, P\u00e9rez-Sirvent ML, Mart\u00ednez D, et\u00a0al. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica. 2008;93:67\u201374.","journal-title":"Haematologica"},{"key":"3469_CR35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","volume":"127","author":"MS Cairo","year":"2004","unstructured":"Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127:3\u201311.","journal-title":"Br J Haematol"},{"key":"3469_CR36","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/BF00860751","volume":"9","author":"DP Jones","year":"1995","unstructured":"Jones DP, Mahmoud H, Chesney RW. Tumor lysis syndrome: pathogenesis and management. Pediatr Nephrol. 1995;9:206\u201312.","journal-title":"Pediatr Nephrol"},{"key":"3469_CR37","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.emc.2018.04.007","volume":"36","author":"K Stephanos","year":"2018","unstructured":"Stephanos K, Picard L. Pediatric oncologic emergencies. Emerg Med Clin North Am. 2018;36:527\u201335.","journal-title":"Emerg Med Clin North Am"},{"key":"3469_CR38","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3109\/10428190903456959","volume":"51","author":"M Darmon","year":"2010","unstructured":"Darmon M, Guichard I, Vincent F, Schlemmer B, Azoulay E. Prognostic significance of acute renal injury in acute tumor lysis syndrome. Leuk Lymphoma. 2010;51:221\u20137.","journal-title":"Leuk Lymphoma"},{"key":"3469_CR39","first-page":"98","volume":"36","author":"LM Nystrom","year":"2016","unstructured":"Nystrom LM, Reimer NB, Reith JD, Scarborough MT, Gibbs CP Jr. The treatment and outcomes of extraskeletal osteosarcoma: institutional experience and review of the literature. Iowa Orthop J. 2016;36:98\u2013103.","journal-title":"Iowa Orthop J"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-022-03469-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-022-03469-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-022-03469-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T23:06:19Z","timestamp":1656371179000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-022-03469-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,28]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3469"],"URL":"https:\/\/doi.org\/10.1186\/s13256-022-03469-6","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,28]]},"assertion":[{"value":"20 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective case report regarding a rare complication of standard of care treatment did not require IRB approval. The deceased patient\u2019s next of kin provided consent for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient\u2018s next of kin for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"252"}}